Cullinan Therapeutics, Inc. — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 24/100
What the filing says
Cullinan Therapeutics will present four posters at the December 2026 ASH Annual Meeting featuring two clinical-stage T cell engager programs: CLN-049 (FLT3xCD3) showing updated Phase 1 dose escalation data in relapsed/refractory AML/MDS at doses of 6 g/kg and 12 g/kg with favorable safety, plus a Phase 1b trial combining CLN-049 with azacitidine and venetoclax in newly diagnosed AML; and velinotamig (CLN-803, BCMAxCD3) with preclinical data and a Phase 1b/2a trial in immune thrombocytopenia and warm autoimmune hemolytic anemia. No financial figures, licensing changes, or material business developments are disclosed.
Why this rating
Conference abstract presentation is routine clinical-stage disclosure with no capital raises, partnerships, or regulatory approvals. Standard visibility event for biotech pipeline advancement.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.